@article{article_392003, title={Adjuvant Chemotherapy in Locally Advanced Bladder Cancer: Retrospective Analysis of 32 Cases}, journal={Journal of Uludağ University Medical Faculty}, volume={37}, pages={123–125}, year={2011}, url={https://izlik.org/JA42ZG53WX}, author={Çubukçu, Erdem and Canhoroz, Mustafa and Ölmez, Ömer Fatih and Avcı, Nilüfer and Çubukçu, Sinem and Akçalı, Ünsal and Sakallı, Mustafa and Bayrak, Muharrem and Kanat, Özkan and Kurt, Ender and et al.}, keywords={Mesane kanseri, lokal ileri , Adjuvan Kemoterapi}, abstract={In this study, patients who received adjuvant chemotherapy for locally advanced bladder cancer were retrospectively analyzed. A total of 32 patients received gemcitabine (%18.8), cisplatin plus gemcitabine (%50), carboplatin plus gemcitabine (%15,6) or MVAC (Methotrexate, vinblastine, doxorubicin, and cisplatin). The most common adverse effect was myelosuppression during chemotherapy administration. Treatment-related died was not observed. The median overall and disease-free survival was 23 months (range, 18.7-27.4) and 17.8 months (range, 12.7-22.9), respectively. We concluded that our results were comparable to those in the literature.}, number={3}